Gastric Volvulus Treatment Market Report 2026

The gastric volvulus treatment market size has grown strongly in recent years. It will grow from $28.86 billion in 2025 to $30.8 billion in 2026 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to availability of surgical treatment options, hospital emergency care growth, diagnosis through imaging tests, development of gastropexy procedures, surgical expertise advancement.

The gastric volvulus treatment market size is expected to see strong growth in the next few years. It will grow to $39.4 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to growth in minimally invasive surgery, improved emergency response systems, adoption of advanced imaging, expansion of specialty surgical centers, increased clinical awareness. Major trends in the forecast period include rising preference for surgical intervention, increased adoption of minimally invasive procedures, improved emergency diagnosis and management, expansion of specialized surgical care, focus on rapid treatment to reduce mortality.

A growing geriatric population is expected to support the expansion of the gastric volvulus treatment market in the coming years. The geriatric population includes individuals aged 65 years and older, who are more susceptible to various health conditions due to age-related decline in immunity and overall physiological function. Gastric volvulus predominantly affects adults over the age of 50, making older populations particularly vulnerable. As a result, the increase in the elderly population is anticipated to boost demand for gastric volvulus treatments. For example, in January 2024, data published by the Population Reference Bureau (PRB), a US-based nonprofit organization, indicated that the population of Americans aged 65 and above is projected to rise from 58 million in 2022 to 82 million by 2050, representing a 47% increase. Additionally, this age group’s share of the total population is expected to grow from 17% to 23%. Consequently, the expanding geriatric population is driving growth in the gastric volvulus treatment market.

Key players in the gastric volvulus treatment market are prioritizing product innovation by developing advanced therapeutic solutions, including next-generation oral immunomodulatory therapies, to address the growing need for more effective and patient-friendly treatment options. These orally administered therapies focus on modulating inflammatory and immune-related pathways, providing a more targeted and convenient alternative to conventional systemic treatments, which often involve higher risks of side effects and complex management. For instance, in October 2023, Pfizer Inc., a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved VELSIPITY (etrasimod). VELSIPITY is a once-daily oral sphingosine-1-phosphate (S1P) receptor modulator indicated for adults with moderate to severe active ulcerative colitis. With a recommended dose of 2 mg, the therapy enables patients to achieve steroid-free disease control through a convenient oral regimen and demonstrates a favorable benefit-risk profile, marking a significant advancement for patients requiring long-term advanced therapy.

In January 2024, Olympus Corporation, a Japan-based medical technology company specializing in imaging systems, endoscopes, and therapeutic solutions, acquired Taewoong Medical Co., Ltd. for approximately $370 million. This acquisition was intended to enhance and diversify Olympus’s gastrointestinal endotherapy portfolio by incorporating Taewoong’s advanced metallic stent technologies. Taewoong Medical, a China-based manufacturer, produces a range of gastrointestinal metallic stents used in the biliary tract, esophagus, colon, and duodenum, supporting minimally invasive treatment of gastrointestinal strictures and obstructions.

Major companies operating in the gastric volvulus treatment market are Medtronic plc, Johnson & Johnson Services Inc., Stryker Corporation, Boston Scientific Corporation, Olympus Corporation, Karl Storz SE & Co KG, Cook Group Incorporated, B Braun Melsungen AG, ConMed Corporation, Fujifilm Holdings Corporation, Pentax Medical (Hoya Corporation), Ambu A S, Richard Wolf GmbH, USGI Medical, Ovesco Endoscopy AG, Endo Tools Therapeutics SA, ErgoSuture, Sutrue Ltd, Golden Stapler Surgical Co Ltd, TransEnterix Inc.

North America was the largest region in the gastric volvulus market in 2025. Asia-Pacific is expected to be the fastest-growing region in the gastric volvulus treatment market report during the forecast period. The regions covered in the gastric volvulus treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gastric volvulus treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the gastric volvulus treatment market by increasing costs of imported surgical instruments, imaging equipment, and hospital supplies. Hospitals and specialty clinics are most affected due to reliance on imported devices. These tariffs increase procedural costs by raising expenses for emergency imaging and surgical intervention, impacting treatment affordability. However, they encourage domestic manufacturing of surgical tools, improving local availability of essential instruments for acute care.

The gastric volvulus treatment market research report is one of a series of new reports that provides gastric volvulus treatment market statistics, including gastric volvulus treatment industry global market size, regional shares, competitors with a gastric volvulus treatment market share, detailed gastric volvulus treatment market segments, market trends and opportunities, and any further data you may need to thrive in the gastric volvulus treatment industry. This gastric volvulus treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gastric volvulus treatment involves surgical management, including reduction of the volvulus, repositioning of the stomach into the abdominal cavity in cases of intrathoracic displacement, and correction of underlying causal factors. Gastric volvulus surgery is generally straightforward and includes de-rotation of the stomach, repositioning of herniated contents into the abdominal cavity, and repair of the hernial defect.

The main types of gastric volvulus treatment include organo-axial and mesentero-axial volvulus. Organo-axial volvulus occurs when the stomach rotates 180 degrees around its long axis, resulting in organo-axial twisting. Treatment options include both medication and surgical intervention, with routes of administration such as oral and parenteral. Distribution channels include hospital pharmacies and retail pharmacies, and these treatments are utilized by hospitals, home healthcare settings, specialty clinics, and others.

The gastric volvulus treatment market includes revenues earned by entities that perform laparotomy, gastric detorsion, and gastric fixation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.